BTK and B-cell chronic lymphocytic leukemia: Interestingly, two of four patients with severe refractory lesions demonstrated complete resolution after treatment for their underlying CLL/SLL [one with venetoclax (BH3‐mimetic) and the other with ibrutinib (BTK inhibitor)].